The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories · page 14 of 23

Stories

  1. Medtronic reports positive real-world registry results for Sphere-9 and PulseSelect at APHRS 2026

    Medtronic said the APEX registry included 1,050 patients with atrial fibrillation treated with the Sphere-9 catheter, reporting a 1.1% major complication rate. The REAL PULSE registry included 1,160 patients and reported a 100% acute success rate with a 0.09% acute major complication rate.

  2. 0.8% of adults with HIV-1 had HIV-1 RNA ≥50 copies/mL at Week 48 on bictegravir/lenacapavir

    At Week 48, 0.8% on bictegravir/lenacapavir and 1.1% on stable baseline therapy had HIV-1 RNA ≥50 copies/mL. The record adds Phase 3 comparative results for adults with suppressed HIV-1 on complex regimens.

  3. Jiangsu Hansoh registers Phase 3 trial of HS-10382 in newly diagnosed Ph+ CML-CP

    The study, led by Jiangsu Hansoh Pharmaceutical Co., Ltd., plans to enroll 408 participants and has a planned start date of December 2026. It evaluates the efficacy of oral HS-10382 versus investigator-selected TKIs-imatinib, nilotinib, dasatinib, and flumatinib-in adult patients with newly diagnosed Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia.

  4. Azafaros registers open-label extension trial of nizubaglustat in rare lysosomal disorders

    The study, NCT07885917, is an open-label roll-over trial to evaluate long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with Niemann-Pick Disease Type C, GM2 Gangliosidosis, GM1 Gangliosidosis, and Gaucher Disease Type 3. It plans to enroll 218 participants, with a start date of December 10, 2026, and primary completion by April 1, 2030.

  5. Kite registers Phase 3 trial of anitocabtagene autoleucel in newly diagnosed multiple myeloma

    The study, iMMagine-4, plans to enroll 600 participants and has a planned start date of January 2027. It plans to compare the safety and efficacy of anitocabtagene autoleucel versus standard of care therapy in participants with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.

  6. Pfizer registers Phase 3 study of RSVpreF revaccination in OLDER ADULTS

    Pfizer has registered a Phase 3, randomized, OPEN-LABEL study to EVALUATE the safety and tolerability of a second dose of RSVpreF given approximately 5 years after the initial dose. The study plans to enroll 750 participants, start on October 29, 2026, and reach primary completion on February 7, 2029.

  7. Seagen posts results of Phase 3 ECHELON-3 trial of brentuximab vedotin in relapsed/refractory DLBCL

    The study enrolled 240 participants and compared brentuximab vedotin plus lenalidomide and rituximab to placebo plus lenalidomide and rituximab. Results were first posted on ClinicalTrials.gov on October 21, 2026.

  8. Gilead posts results of ARTISTRY-1 bictegravir/lenacapavir study

    The study, enrolling 689 participants, compared bictegravir/lenacapavir to stable baseline regimens in virologically suppressed people with HIV-1. Results were first posted on ClinicalTrials.gov on October 21, 2026.

  9. Janssen posts Phase 3 ustekinumab results in pediatric ulcerative colitis

    Janssen Research & Development, LLC posted results of a Phase 3 ustekinumab study in 112 participants with moderately to severely active ulcerative colitis. The record lists 25 percent in clinical remission at induction Week 8.

  10. Phase 3 results posted, week of October 19, 2026: 5 industry trials

    Industry sponsors posted results for 5 Phase 3 trials on ClinicalTrials.gov in the week of October 19 to 25, 2026. Together the trials enrolled 2,508 participants; the largest, Merck Sharp & Dohme's Pembrolizumab trial, enrolled 1,174.

  11. Amgen and AstraZeneca report Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis

    The Phase 3 CROSSING trial showed TEZSPIRE achieved histologic remission in 64.8% (210 mg) and 68.9% (420 mg) of patients at week 24 versus 3.5% on placebo (p<0.001). The Dysphagia Symptom Questionnaire score decreased by 18.8 points (210 mg) and 22.0 points (420 mg) versus 14.7 points on placebo, with reductions sustained through week 52.

  12. GC Biopharma registers Phase 2/3 trial of GC3114B in adults 65 years or older

    The study plans to enroll 1806 participants and is expected to begin in October 2026. It is a multicenter, randomized, double-blind, active-controlled trial that will evaluate the safety of GC3114B and assess whether its immune response is non-inferior to that of the active control.